Creo Medical Limited
CREO.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.17 | 0.13 | 0.00 | -1.34 |
| FCF Yield | -32.05% | -15.84% | -59.57% | -12.65% |
| EV / EBITDA | -2.54 | -7.21 | -1.67 | -8.02 |
| Quality | ||||
| ROIC | -58.87% | -31.47% | -42.22% | -28.16% |
| Gross Margin | 47.50% | 49.68% | 36.84% | 35.86% |
| Cash Conversion Ratio | 0.80 | 1.00 | 0.93 | 1.06 |
| Growth | ||||
| Revenue 3-Year CAGR | -47.20% | 6.97% | 42.30% | 1,131.46% |
| Free Cash Flow Growth | 0.88% | 19.33% | 11.96% | -92.68% |
| Safety | ||||
| Net Debt / EBITDA | 0.16 | -0.26 | 0.05 | 1.20 |
| Interest Coverage | -72.00 | -62.00 | -124.22 | -82.53 |
| Efficiency | ||||
| Inventory Turnover | 0.78 | 1.91 | 1.84 | 1.90 |
| Cash Conversion Cycle | 431.48 | 220.78 | 174.06 | 177.02 |